{"id":892272,"date":"2025-10-03T09:19:08","date_gmt":"2025-10-03T13:19:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/"},"modified":"2025-10-03T09:19:08","modified_gmt":"2025-10-03T13:19:08","slug":"coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/","title":{"rendered":"Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)"},"content":{"rendered":"<h2>\n\u2013 CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC\u2019s upcoming webinar series \u201cTargets for Cancer IO: A Deep Dive\u201d on October 22, 2025 \u2013<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>REDWOOD CITY, Calif., Oct.  03, 2025  (GLOBE NEWSWIRE) &#8212; Coherus Oncology, Inc.\u00a0(NASDAQ: CHRS), today announced an upcoming poster presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 5-9, 2025, in National Harbor, Maryland.<\/p>\n<p>\n        <strong>Abstract # 640: <\/strong><br \/>\n        <strong><br \/>\n          <em>CHS-114, an anti-CCR8 cytolytic monoclonal antibody demonstrates selective intratumoral Treg depletion and favorable immune remodeling in participants with advanced solid tumors<\/em><br \/>\n        <\/strong><br \/>\n        <em>.<\/em>\n      <\/p>\n<ul type=\"disc\">\n<li>Date: Saturday, November 8, 2025<\/li>\n<li>Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center<\/li>\n<\/ul>\n<p>In addition, CHS-114 will be featured in the upcoming <strong>Targets for Cancer IO: A Deep Dive<\/strong>\u00a0live webinar series: <br \/><strong>Development of Anti-CCR8 Ab &#8211; Mechanisms and Clinical Results<\/strong><br \/>Webinar 6 will address the novel therapeutic target C-C chemokine receptor 8 (CCR8), its role in regulatory T cell (Treg) activity and immunosuppression, and the latest advances and insights in developing monoclonal antibodies that target this chemokine receptor as a promising new strategy to treat a variety of cancers.<\/p>\n<ul type=\"disc\">\n<li>Date and Time: October 22, 2025, 12:00 \u2013 2:00 pm Eastern Time<\/li>\n<li>Moderators: Enrico Lugli, PhD, <em>Humanitas Research Hospital and <\/em>Rahul Roychoudhuri, MD, PhD<br \/><em>University of Cambridge<\/em><\/li>\n<li>Faculty: Rosh Dias, MD, MRCP, <em>Coherus Oncology; <\/em>Varun Kapoor, PhD, <em>Coherus Oncology; <\/em>Jo Van Ginderachter, PhD, <em>Vrije Universiteit Brussel<\/em><\/li>\n<\/ul>\n<p>To learn more about the webinar series and register to attend, visit SITC\u2019s Targets for Cancer IO: A Deep Dive website: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JI57aW6pbyD5olrG42mWT0wX0AXdFskFAD0wag-OmyuorqxXC6ev8bYlmINbce-WIDZY_1AOkp1ZgZUQkW1V0U-oqbvx528gjB97rtoleZ0qTBNT96kAx51MXzQ1Zcp0zmGDT5bnYgfyRrZ_y7c3lWWGB-dJbdB7OSMNhqYn2xnxi08HWNupddsao3-fQhmkGPOVO-PrxsxsnV7-HR7aDQ==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.sitcancer.org\/edu\/webinars\/targets-for-cancer-io<\/a><\/p>\n<p>\n        <strong>About Coherus Oncology<\/strong>\n      <\/p>\n<p>Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI\u00ae (toripalimab-tpzi), growing revenues and a promising proprietary pipeline that includes two mid-stage clinical candidates targeting liver, lung, head &amp; neck, colorectal and other cancers. The Company\u2019s strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its partners, driving sales multiples and synergies from proprietary combinations.<\/p>\n<p>Coherus\u2019 immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in multiple Phase 1\/2 and Phase 2 studies in patients with advanced solid tumors, including non-small cell lung cancer and HCC. CHS-114 is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b\/2a studies in patients with advanced solid tumors, including head and neck cancer, colorectal cancer, gastric cancer, and esophageal cancer.<\/p>\n<p>For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zP28Xaesu3DYpIUlcBwiJMwtbWgFg8CYtw9RdErKpYERXqXtYkkWZ_2VOT1yI5rQMlXScYh0TvbLeE4xH83Vwq1m3V0K7_j2g_vhgjJZ-x8=\" rel=\"nofollow\" target=\"_blank\">www.loqtorzi.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>The statements in this press release include express or implied forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act about Coherus that involve risks and uncertainties relating to future events and the future performance of Coherus. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. Words such as \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cfuture,\u201d \u201copportunity,\u201d \u201clikely,\u201d \u201ctarget,\u201d variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. You can also identify forward-looking statements by discussions of strategy, plans or intentions.<\/p>\n<p>Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding: the ability of Coherus\u2019 pipeline to enhance outcomes for cancer patients; expectations about future synergies; projections about growth in sales or revenues; expectations about advancing product candidates through clinical trials; and the assumptions underlying or relating to such statements.<\/p>\n<p>These forward-looking statements are based on Coherus\u2019 current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, assumptions and changes in circumstances, many of which are beyond the control of Coherus. A number of important factors, including those described in this press release, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: uncertainties about the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, economic performance, indebtedness, financial condition and losses on Coherus\u2019 prospects, business and operations in the future; risks and uncertainties of conducting clinical trials; the risks of Coherus\u2019 dependence on an ability to raise funds, which may not be available on acceptable terms or at all; and risks and uncertainties of any litigation, regulatory actions and other legal proceedings.<\/p>\n<p>While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. There can be no assurance that the transaction described above will in fact be consummated in the manner described or at all. For a further discussion of these and other factors that could cause Coherus\u2019 future results to differ materially from any forward-looking statements see the section entitled \u201cRisk Factors\u201d in Coherus\u2019 Quarterly Report on Form 10-Q for the period ended June 30, 2025, filed with the Securities and Exchange Commission (SEC) on August 7, 2025, as updated by Coherus\u2019 subsequent reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are made based on the current good faith beliefs and judgments of Coherus\u2019 management, and the reader is cautioned not to rely on any forward-looking statements made by Coherus. Unless required by law, Coherus is not under any duty and undertakes no obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes.<\/p>\n<p>LOQTORZI<sup>\u00ae<\/sup> is a registered trademark of Coherus Oncology, Inc. <br \/>\u00a92025 Coherus Oncology, Inc. All rights reserved.<\/p>\n<p>\n        <strong>Coherus Oncology Contact Information:<\/strong>\n      <\/p>\n<p>For Investors:<br \/>Jodi Sievers<br \/>VP, Investor Relations &amp; Corporate Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3Qf_3QzHcVFd8mfg4ULH9xJePjbqbyYzui7DJAX_gSR2V2aVop7W_06B7dCikDcoQAgc86zxXfSV57AhtPd5QQ==\" rel=\"nofollow\" target=\"_blank\">IR@coherus.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTY5MiM3MTc3OTE3IzIwMTExNTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjZiMWMzMzItYWFlMC00MTA5LTgxYzgtZDExYWY2Y2I1NzNkLTEwMjI3MzEtMjAyNS0xMC0wMy1lbg==\/tiny\/Coherus-BioSciences-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2013 CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC\u2019s upcoming webinar series \u201cTargets for Cancer IO: A Deep Dive\u201d on October 22, 2025 \u2013 REDWOOD CITY, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) &#8212; Coherus Oncology, Inc.\u00a0(NASDAQ: CHRS), today announced an upcoming poster presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 5-9, 2025, in National Harbor, Maryland. Abstract # 640: CHS-114, an anti-CCR8 cytolytic monoclonal antibody demonstrates selective intratumoral Treg depletion and favorable immune remodeling in participants with advanced solid tumors . Date: Saturday, November 8, 2025 Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center In addition, CHS-114 will be featured in the upcoming Targets &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-892272","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2013 CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC\u2019s upcoming webinar series \u201cTargets for Cancer IO: A Deep Dive\u201d on October 22, 2025 \u2013 REDWOOD CITY, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) &#8212; Coherus Oncology, Inc.\u00a0(NASDAQ: CHRS), today announced an upcoming poster presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 5-9, 2025, in National Harbor, Maryland. Abstract # 640: CHS-114, an anti-CCR8 cytolytic monoclonal antibody demonstrates selective intratumoral Treg depletion and favorable immune remodeling in participants with advanced solid tumors . Date: Saturday, November 8, 2025 Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center In addition, CHS-114 will be featured in the upcoming Targets &hellip; Continue reading &quot;Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-03T13:19:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTY5MiM3MTc3OTE3IzIwMTExNTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)\",\"datePublished\":\"2025-10-03T13:19:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\\\/\"},\"wordCount\":1032,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzOTY5MiM3MTc3OTE3IzIwMTExNTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\\\/\",\"name\":\"Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzOTY5MiM3MTc3OTE3IzIwMTExNTg=\",\"datePublished\":\"2025-10-03T13:19:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzOTY5MiM3MTc3OTE3IzIwMTExNTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzOTY5MiM3MTc3OTE3IzIwMTExNTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/","og_locale":"en_US","og_type":"article","og_title":"Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - Market Newsdesk","og_description":"\u2013 CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC\u2019s upcoming webinar series \u201cTargets for Cancer IO: A Deep Dive\u201d on October 22, 2025 \u2013 REDWOOD CITY, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) &#8212; Coherus Oncology, Inc.\u00a0(NASDAQ: CHRS), today announced an upcoming poster presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 5-9, 2025, in National Harbor, Maryland. Abstract # 640: CHS-114, an anti-CCR8 cytolytic monoclonal antibody demonstrates selective intratumoral Treg depletion and favorable immune remodeling in participants with advanced solid tumors . Date: Saturday, November 8, 2025 Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center In addition, CHS-114 will be featured in the upcoming Targets &hellip; Continue reading \"Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-03T13:19:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTY5MiM3MTc3OTE3IzIwMTExNTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)","datePublished":"2025-10-03T13:19:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/"},"wordCount":1032,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTY5MiM3MTc3OTE3IzIwMTExNTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/","name":"Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTY5MiM3MTc3OTE3IzIwMTExNTg=","datePublished":"2025-10-03T13:19:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTY5MiM3MTc3OTE3IzIwMTExNTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTY5MiM3MTc3OTE3IzIwMTExNTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-announces-poster-presentation-at-the-40th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892272","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=892272"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892272\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=892272"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=892272"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=892272"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}